- CITATIONS: 1
|Application ||WB, E|
|Calculated MW||62056 Da|
|Antigen Region||523-552 aa|
|Other Names||Protein ENL, YEATS domain-containing protein 1, MLLT1, ENL, LTG19, YEATS1|
|Target/Specificity||This MLLT1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 523-552 amino acids from the C-terminal region of human MLLT1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||MLLT1 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||ENL, LTG19, YEATS1|
|Function||Component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA.|
Provided below are standard protocols that you may find useful for product applications.
Chromosome band 11q23 is the site of translocations in myeloid and lymphoid acute leukemias, pediatric leukemias, and treatment-induced secondary acute myelogenous leukemia. The translocation breakpoints cluster in a restricted region of the HRX gene resulting in chimeric genes that encode an N-terminal portion of Hrx fused to various partner proteins. Myeloid/lymphoid or mixed-lineage leukemia translocated to 1 (MLLT1) is a nuclear protein with transcriptional transactivation properties that is fused to Hrx in t(11;19) leukemias. The minimal MLLT1 sequence required for transcription activation was narrowed to the C-terminal 90 amino acids.
Nie, Z., et al., Mol. Cell. Biol. 23(8):2942-2952 (2003).
Lavau, C., et al., Proc. Natl. Acad. Sci. U.S.A. 97(20):10984-10989 (2000).
Thirman, M.J., et al., Proc. Natl. Acad. Sci. U.S.A. 91(25):12110-12114 (1994).
Rubnitz, J.E., et al., Blood 84(6):1747-1752 (1994).
Yamamoto, K., et al., Oncogene 8(10):2617-2625 (1993).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.